RSS
Home
SEE THE LATEST ON THIS STORY
The drug company’s estimates are preliminary and will not be finalized until May 3.
The earnings jump was attributed to improved sales of Synagis, the company’s lung infection drug.
National 
Business
Business
MedImmune reports it triples first quarter profits
903 days ago: AstraZeneca clears key hurdle in MedImmune acquisition
907 days ago: FluMist for young children put on hold
923 days ago: Gene Logic partners with pharmaceutical giant Abbott
928 days ago: States, D.C., to share $19.5M in OxyContin settlement
944 days ago: Gaithersburg’s MedImmune sold for $15.2 billion
944 days ago: Advancis closes private placement, raises $24 million
944 days ago: MedImmune commits to sale agreement
» 958 days ago: MedImmune reports it triples first quarter profits «
964 days ago: Drug companies spend record sums on lobbying
Related Topics: Gaithersburg
Gaithersburg
(Map, News)
-
Gaithersburg-based MedImmune posted earnings ranging from 62 cents to 67 cents per share in the first quarter, up from 23 cents per share in first quarter 2006.
Add a Comment
Your comments will appear shortly after they are posted.There are no comments available.
